Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease.
10.3760/cma.j.cn501113-20220130-00053
- Collective Name:Severe Liver Disease Group, the Professional Committee for Hepatology, Chinese Research Hospital Association;Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association
- Publication Type:Journal Article
- Keywords:
Consensus;
Diagnosis;
Invasive fungal infection;
Prevention;
Severe liver disease
- MeSH:
Antifungal Agents/therapeutic use*;
Consensus;
Humans;
Invasive Fungal Infections/therapy*;
Liver Diseases/drug therapy*
- From:
Chinese Journal of Hepatology
2022;30(2):159-168
- CountryChina
- Language:Chinese
-
Abstract:
The prognosis of severe liver disease combined with invasive fungal infection (IFI) is poor, and the clinical manifestations are often atypical. Moreover, most of the antifungal drugs are metabolized in the liver, with severe toxicities and side effects, making clinical diagnosis and treatment difficult. The Professional Committee for Hepatology, the Chinese Research Hospital Association and the Hepatology Branch of China Medical Association organized relevant experts to formulate an expert consensus based on the characteristics of patients with severe liver disease combined with IFI, in order to provide reference for medical personnel in making decisions on the diagnosis and treatment.
